tirzepatide news november 2025 In adults with obesity but not diabetes, leads to significantly greater weight loss than semaglutide over 72 weeks, and nearly double the patients on tirzepatide meet the 25% weight-loss target. http://ms.spr.ly/6183SkuIL Tirzepatide Leads Pharma Growth in

The genomic landscape of endocrine-resistant advanced breast cancers

You Have Specific Metabolic Needs Semaglutide is particularly beneficial for individuals who also need: Cardiovascular Protection: New 2026 data confirms it significantly lowers the risk of heart attack and stroke

You can read the full article at Sanionas tesofensine meets primary and secondary endpoints in Phase 3 obesity registration trial Biotech company Saniona has announced positive results from its Phase 3 Viking study evaluating the weight loss potential of tesofensine in obese patients

Whether youre looking for the convenience of a once-weekly injection or a needle-free daily capsule, our providers will help you choose the option thats right for you

These side effects are transient and typically subside within a day or two following injection